Business Intelligence on Biologic and Small Molecule Drugs
Figure 1 – More than half of the follow-up collaborations relied exclusively on some sort of in-kind contribution
Figure 1. More than half of the follow-up collaborations signed have relied exclusively on some sort of in-kind contribution (leveraging only existing Lilly internal infrastructure and/or scientific capabilities). The remaining balance, or incentive collaborations, comprises those cases where the relevant experimental work (shown in the bar chart) is instead completed by the partner, after the transfer of financial support from Lilly.